Impedimed (ASX:IPD) share price rises with 46% lift in revenues

Let's take a closer look.

| More on:
heavy lifting, lifting index, carrying weight, boy lifting dumbbell above his head

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Impedimed Limited (ASX: IPD) share price is appreciating after the company released its full-year results for FY21.

At the time of writing, shares in the healthcare company are trading for 13 cents each – up 4%. For context, the ASX All Ordinaries Index (ASX: XAO) is 0.25% higher.

Let's take a closer look at today's announcement.

Impedimed share price lifts with reduction in losses

  • Revenue of $8.4 million – up 46.5% on the prior corresponding period (pcp). This includes a 64% growth in revenue from its SOZO software, which totalled $7.6 million.
  • Loss from ordinary activities of $20.7 million, which is down 3% on the pcp.
  • Net operating cash outflows for the period of $13.3 million. This is down from the $19.2 million outflow in the pcp.
  • Nil dividend paid for the year, which is the same as FY20.

What happened in FY21 for Impedimed?

The Impedimed share price rocketed 13% in November when AstraZeneca plc (LSE: AZN) announced it was using SOZO for phase II clinical trials. The product was used for measuring fluid volumes in patients with chronic kidney disease.

Besides SOZO, Impedimed also announced news in relation to its 'Prevent' treatment and 'HF-Dex' system.

What did management say?

Impedimed CEO and Managing Director, Richard Carreon, said

Our transition to a connected digital health platform put the Company in a strong position to thrive during a very turbulent year. We have built a strong and resilient business, with quarter-over-quarter record results. Throughout the past year, our Company continued to prove its resilience, as we signed SOZO contracts in excess of $12.0 million, had a churn rate of just 1%, and a contract renewal rate of 100% throughout the entire financial year.

What's next for Impedimed?

Just in the last 2 days, Impedimed released 2 statements that were material to the Impedimed share price.

The first relates to designation of a product in the US and the second on an R&D tax rebate.

On the first matter, SOZO received "Breakthrough Device Designation" from the US Food and Drug Administration (FDA) for use in renal patients. The product will be used to measure fluids in patients undergoing dialysis. The company says the designation is the "perfect forum" to ultimately get FDA clearance.

On the second, the company received a $1.8 million research and development (R&D) from the Australian government. Last year the company received a $2.6 million refund.

Impedimed share price snapshot

Over the past 12 months, the Impedimed share price has increased 62.5%. Year-to-date, however, it is only up 8.33%. This is below the All Ords Index. Impedimed has a market capitalisation of about $187 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

Why Boss Energy, Emeco, Mineral Resources, and Plenti shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Share Gainers

3 ASX 300 shares going gangbusters on Wednesday

Investors are bidding up these three ASX 300 shares today. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a huge Tuesday for ASX shares, with the index resetting its record high.

Read more »

Woman holding gold bar and cheering.
Gold

Why are ASX gold shares rebounding today?

ASX investors are going for gold today.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

Why Meteoric Resources, Resolute Mining, Sonic Healthcare, and TechnologyOne shares are roaring higher

Let's see why investors are getting excited about these shares on Tuesday.

Read more »

Two kids in superhero capes.
Small Cap Shares

Guess which 2 ASX small-cap shares just rocketed 50%+ on big news!

Investors are sending these two ASX small-cap stocks through the roof on Tuesday.

Read more »